Loading...
NPI 1548373855 · Great Neck, NY · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Eric Shakin is a ophthalmology physician provider located in Great Neck, New York. This profile covers 24 Medicare and 12 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Eric Shakin |
| Address | 600 Northern Blvd |
| City | Great Neck |
| State | NY |
| ZIP | 11021 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | August 17, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $3.3M |
| Medicaid | $291.7K |
Practice is retina- and injection-focused: the provider’s top Medicare revenue drivers are J0178, Q5128, and J2777, and the code mix (large volumes of aflibercept and other intravitreal drug codes plus retina imaging) indicates an operational emphasis on intravitreal injections and retinal specialty care rather than primarily general ophthalmology office visits. This aligns with high-use procedural codes and drug administration as the center of clinical throughput.
Medicare revenue is highly concentrated in a few drug codes: the precomputed top three Medicare codes account for 71.3% of this provider’s total Medicare revenue, with J0178 alone representing a majority share (51.3% of Medicare revenue). That concentration creates strong reliance on a small set of high-revenue biologic injections for the practice’s Medicare income.
Medicaid revenue is even more concentrated around intravitreal therapy and injection procedures: the top three Medicaid codes (J0178, 67028, J2778) account for 88.2% of this provider’s total Medicaid revenue, with J0178 at 48.2% and 67028 at 27.4% of Medicaid revenue. This pattern shows the same procedural/drug-driven business model carries through the provider’s Medicaid billing.
Payer mix is heavily Medicare‑weighted: the provider reported Total Medicare revenue of $3.3M versus Total Medicaid revenue of $291.7K, indicating Medicare is the dominant payer for this practice’s billed services. Medicaid exists as a smaller but still focused revenue stream centered on the same injection and procedure codes.
Competitive standing on key codes is mixed: for J0178 the provider ranks #343 of 3204 nationally (89th percentile), indicating above-average national placement for aflibercept billing; Q5128 ranks #86 of 373 (77th percentile) and J2777 ranks #896 of 2039 (56th percentile), both described as typical volumes relative to peers. In-state for Medicaid, J0178 ranks #44 of 101 (57th percentile) while 67028 ranks #47 of 262 (82nd percentile), showing stronger relative activity regionally for the injection procedure 67028.
Imaging and established-patient evaluation volumes are notable outliers: code 92134 is a national extreme outlier (98th percentile; far above typical national volume) and codes 92012 (96th percentile) and 99213 (97th percentile) are described as notably above typical national volume. Those high-percentile signals point to a high-throughput clinic workflow that pairs frequent retinal imaging and follow-up E/M visits with injection visits.
Operational and payer-risk implications follow from drug/resource concentration: with J0178 accounting for 51.3% of Medicare revenue and large shares of Medicaid revenue, the practice is exposed to changes in drug reimbursement, biosimilar adoption, or procurement costs for intravitreal biologics. Payers and network managers should view this provider as a specialty revenue center where drug-reimbursement policy changes could materially affect provider economics.
Tenure supports established referral patterns: the NPI has been enumerated since 2006-08-17 (~20 years ago), indicating long-standing presence in the market that is consistent with building a sustained procedural retina practice and the high-volume imaging and injection pattern observed.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
24 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 2,430 | $690 | $1.7M |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 1,520 | $220 | $330.1K |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 11,640 | $30 | $325.9K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 1,790 | $110 | $193K |
| J3490 | Unclassified drugs | 80 | $2,000 | $164.2K |
| J2778 | Injection, ranibizumab, 0.1 mg | 770 | $190 | $143.1K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 2,950 | $40 | $106.1K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 870 | $80 | $70.2K |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | 480 | $120 | $57.6K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 700 | $80 | $53.1K |
Showing 1–10 of 24
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 24 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
24 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 26 | 230 | 560 | $690 | $693K |
| J2777 | 38 | 120 | 7,740 | $30 | $364.9K |
| Q5128 | 6 | 20 | 1,170 | $220 | $268.3K |
| J2778 | 25 | 70 | 510 | $180 | $131.6K |
| J2781 | 23 | 40 | 520 | $120 | $75.1K |
| Q5124 | 19 | 20 | 310 | $170 | $69.7K |
| 67028 | 25 | 300 | 400 | $100 | $65.9K |
| J3490 | 47 | 120 | 60 | $470 | $50.8K |
| 92014 | 541 | 2,220 | 160 | $100 | $29.3K |
| 99214 | 26,701 | 30,450 | 90 | $100 | $19K |
Showing 1–10 of 24
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
12 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 360 | $390 | $140.4K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 1,730 | $50 | $79.7K |
| J2778 | Injection, ranibizumab, 0.1 mg | 110 | $330 | $36.8K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 2,300 | $10 | $20.7K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 300 | $30 | $8.5K |
| 92226 | N/A | 350 | $10 | $3.1K |
| 92201 | The provider performs an extended ophthalmoscopy, typically with an indirect ophthalmoscope which utilizes a bright light and a hand–held indirect lens rather than the common hand–held one–piece… | 140 | $10 | $950 |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 20 | $40 | $660 |
| J9035 | Injection, bevacizumab, 10 mg | 10 | $20 | $250 |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 10 | $10 | $170 |
Showing 1–10 of 12
How this provider's Medicaid billing volume and revenue compare to other New York providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New York median
12 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 44 | 100 | 280 | $650 | $369.9K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 18,474 | 19,110 | 360 | $70 | $321K |
| J2778 | Injection, ranibizumab, 0.1 mg | 6 | 10 | 110 | $500 | $160.1K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 2,193 | 2,440 | 330 | $70 | $92.6K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 737 | 1,460 | 310 | $60 | $88.1K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 47 | 260 | 420 | $70 | $65.6K |
| J9035 | Injection, bevacizumab, 10 mg | 136 | 150 | 170 | $80 | $36.7K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 125 | 730 | 370 | $20 | $30K |
| 92226 | N/A | 176 | 400 | 270 | $20 | $12.6K |
| 92201 | The provider performs an extended ophthalmoscopy, typically with an indirect ophthalmoscope which utilizes a bright light and a hand–held indirect lens rather than the common hand–held one–piece… | 176 | 320 | 190 | $20 | $10.7K |
Showing 1–10 of 12
Other providers in the same ZIP code as Eric Shakin, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| C And T Homecare Services LLC | NY | In Home Supportive Care Agency | $0 | $847.7M |
| First Choice Home Care Inc | NY | Home Health Agency | $0 | $28M |
| Welllife Network Inc. | NY | Clinic/Center | $0 | $22M |
| Regioncare Inc. | NY | Home Infusion Agency | $40.1K | $9.4M |
| David Fastenberg | NY | Ophthalmology Physician | $4.4M | $31.2K |
| David Rhee | NY | Ophthalmology Physician | $4M | $73.4K |
| Vincent Deramo | NY | Ophthalmology Physician | $4M | $15.1K |
| Juan Romero | NY | Ophthalmology Physician | $3.1M | $441.8K |
| Philip Ferrone | NY | Ophthalmology Physician | $3.1M | $10.5K |
| Shahram Shamekh | NY | Internal Medicine Physician | $673.3K | $1.4M |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.